Lakefront Biotherapeutics (LKFT) Share-based Compensation (2016 - 2020)

Lakefront Biotherapeutics (LKFT) has reported Share-based Compensation for 5 consecutive years, with $33.5 million the latest figure, recorded in Q2 2020.

• In Q2 2020, Share-based Compensation rose 177.31% year-over-year to $33.5 million; the TTM figure through Jun 2020 stood at $67.6 million (up 79.92% YoY), while the FY2023 annual figure was $61.0 million, down 32.42% from the prior year.
• Share-based Compensation climbed to $33.5 million in Q2 2020 per LKFT's latest filing, from $10.2 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $7.7 billion in Q2 2017 and bottomed at -$8.2 billion in Q3 2017.
• Historically, Share-based Compensation has averaged -$24.1 million across 5 years, with a median of $8.3 million in 2018.
• Annual changes were most pronounced in 2017 — Share-based Compensation jumped 289559.74% — and 2018, when it plunged 99.9%.
• Lakefront Biotherapeutics' Share-based Compensation stood at $2.6 million in 2016, then jumped by 34.63% to $3.6 million in 2017, then surged by 180.78% to $10.0 million in 2018, then rose by 12.63% to $11.3 million in 2019, then jumped by 197.62% to $33.5 million in 2020.
• Business Quant data shows LKFT's Share-based Compensation at $33.5 million in Q2 2020, $10.2 million in Q1 2020, and $11.3 million in Q4 2019.